"GX-19" from_date:2012

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers. This clinical study is phase 1/2a clinical trial to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive vaccine by intramuscularly

Healthcare Limited DNA plasmid vaccine Phase 1 / 2 CTRI/2020/07/026352 15. DNA Vaccine (GX-19) Genexine Consortium DNA Vaccine (GX-19) Phase 1 / 2 NCT04445389 16. Whole-Virion Inactivated Bharat Biotech Whole-Virion Inactivated Phase 1 / 2 NCT04471519 17. INO-4700 Inovio Pharmaceuticals/ International Vaccine Institute DNA plasmid vaccine with electroporation Phase 1 / 2 NCT04447781 18. RBD-based

-19) Genexine Consortium DNA Vaccine (GX-19) Phase 1 / 2 NCT04445389 16. Whole-Virion Inactivated Bharat Biotech Whole-Virion Inactivated Phase 1 / 2 NCT04471519 17. INO-4700 Inovio Pharmaceuticals/ International Vaccine Institute DNA plasmid vaccine with electroporation Phase 1 / 2 NCT04447781 18. RBD-based Kentucky Bioprocessing, Inc RBD-based Phase 1 / 2 NCT04473690 19. mRNA Arcturus of Microbiology, Chinese Academy of Sciences Adjuvanted recombinant protein (RBD-Dimer) Phase 2 NCT04466085 12. mRNA Curevac mRNA Phase 2 NCT04515147 13. DNA plasmid vaccine + Adjuvant Osaka University/ AnGes/ Takara Bio DNA plasmid vaccine + Adjuvant Phase 1 / 2 NCT04463472 14. DNA plasmid vaccine Cadila Healthcare Limited DNA plasmid vaccine Phase 1 / 2 CTRI/2020/07/026352 15. DNA Vaccine (GX